SK Bapharm acquires US 'ProtoVant Science’'

Reporter Paul Lee / approved : 2023-07-03 05:44:53
  • -
  • +
  • 인쇄

 

 

[Alpha Biz=(Chicago) Reporter Paul Lee] SK Group acquired the US bio company Proteovant Science through SK Biopharm and established a research base for finding new drug candidates there for the first time since its foundation.

Prior to this, SK Life Science established a clinical development and direct sales system in the United States. SK Farm Teco, a global pharmaceutical consignment development (CDMO) company, has its headquarters and production facilities in the United States.

SK Biopharm announced on the 30th that it will acquire a 60.0% stake in the US bio company Proteovant Science for 61.95325 billion won. The acquisition fund amounts to 19.6% of SK Biopharm's equity capital. The acquisition date of the stake is July 17th.

Proteovant Science is a joint venture (JV) co-founded by SK and Swiss-based bio company Roivant in March 2020. SK Biopharm secured a total of 60% of Roiband's stake and held a 100% stake with SK, which holds the remaining 40%.

 

Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)

주요기사

[Exclusive] Samsung Electronics Passes NVIDIA’s HBM3E 12-High Qualification Test, Secures Supply Deal2025.09.19
Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사